Author: admin

buy trenbolone enanthate

Published / by admin

Tissue regeneration stimulator of plant origin.

Has a local anti-inflammatory and stimulating buy trenbolone enanthate effect of regeneration processes, it helps cleanse wounds and ulcers of necrotic tissue.

Trophic ulcers, non-healing wounds, burns, bedsores, cracked nipples in nursing mothers, and various inflammatory diseases of the oral cavity and periodontal (aphthous stomatitis, gingivitis, periodontitis).

Dosage and administration:
Outwardly. The wound or ulcer drug irrigate (1-3 ml) and put gauze bandage (4-5 layers), abundantly soaked buy trenbolone enanthate drug. Fold change first day, then every other day.Once a day, further the lower layers of moistened dressings preparation (removing the top layers). Average duration of treatment 15-20 days.
If cracked nipples after each feeding nipple pipetted few drops of the drug. The duration of treatment is 4-5 days. In dentistry, the preparation is applied topically in the form of applications for daily oral mucosa, 3-4 times a day; application duration is 15-20 minutes. The course of treatment – 1-2 weeks.

Side effects:
Allergic reactions. In rare cases – a burning sensation in the wound.

Specific guidance
in case of burning sensation in the wound were added 2 ml of a 2% novocaine solution per 100 ml formulation.
Medication before use should be kept at room temperature for at least 30 minutes.
In dental practice, the drug prior to use in a water bath heated to a temperature of +37 ° C .

Product form
The solution for local and external application of alcohol; 20 mL neutral glass vials. Each bottle with instruction on use are placed in the pack.

Storage conditions
In buy trenbolone enanthate the dark and inaccessible to children at temperature from +18 to +20 ° C Rising.

Shelf life
2 years. Do not use beyond the expiration date printed on the package.

Terms of pharmacies vacation
is sold without a prescription.

Buy steroids in our shop

trenbolone enanthate cycle

Published / by admin

Used as monotherapy after prior chemotherapy that included trastuzumab, and drugs from the group of taxanes (sequentially or in combination), or after disease progression trenbolone enanthate cycle during or within 6 months after completion of adjuvant therapy, including trastuzumab, and drugs group taxanes (sequentially or in combination) in patients with unresectable locally advanced or metastatic positive breast cancer.

Hypersensitivity to trastuzumab emtanzinu to other trenbolone enanthate cycle components of the preparation.
Infuzionnnye reactions associated with the use of trastuzumab, which led to the cancellation of therapy.
Pregnancy and lactation.
Age 18 years (effectiveness and safety of use in children has not been established).
Diffuse interstitial lung disease, pneumonitis.
Increase in trenbolone enanthate cycle amintoransferaz> 3hverhney limit of normal (ULN) or total bilirubin concentration> 2hVGN. Nodal regenerative hyperplasia of the liver. . Symptomatic congestive heart failure,
renal failure, severe and terminal degree (creatinine clearance <30 mL / min), liver failure (efficacy and safety have not been established).
The value of ejection fraction of the left ventricle trenbolone enanthate cycle before treatment; Chronic heart failure in history; dyspnea at rest due to the progression of malignant disease or concomitant diseases; serious cardiac arrhythmia requiring drug therapy; myocardial infarction or unstable angina, which evolved during the 6 months prior to treatment; platelet count prior to treatment; peripheral neuropathy >Grade 3 prior to treatment (efficacy and safety have not been established).

The caution
in trenbolone enanthate cycle transaminases> or the concentration of total before treatment before treatment, before or after adjuvant treatment with paclitaxel,
prior or simultaneous use of antihypertensive drugs,
prior anthracycline therapy;
aged> patients 50 years
in patients with a body mass index> 25 kg / m 2 .

Use during pregnancy and during breastfeeding

Women have reproductive potential and male patients, as well as women of childbearing age who are sexual partners of patients receiving the drug Quds ® , must use effective contraception during treatment with Quds ® and for 6 months after the last dose. In case of pregnancy the patient should consult a doctor immediately.
It is necessary to warn women about the possibility of harmful effects on the fetus. If a pregnant woman chooses to continue therapy with Quds ® , it should be under close medical supervision.
It is not known whether trastuzumab emtanzin into breast milk. Breast-feeding is not recommended during treatment and for at least 6 months after the end of therapy with Quds ® .

Dosing and Administration

Before using the drug you need to check the label on the bottle and make sure that used for the preparation and administration of the drug is a Quds drug ® (trastuzumab emtanzin), rather than the drug Gertseptink (trastuzumab).
Use of the drug Quds ® should only be done under the supervision of a physician with experience treatment of cancer.
It is necessary to carry out testing for the expression of HER2 tumor before treatment with Quds ® . Essential criteria a score of 3+ on the results of immunohistochemistry (IHC) and / or the degree of amplification of > 2.0 as a result of hybridization in situ conservation (the ISH). The methods used should be validated test.
The patient’s medical records should indicate the trade name of the drug (Quds ® ). Replacement product Quds ® to another drug of biological origin should be agreed with your doctor. Dosage The recommended dose Quds drug ® is 3.6 mg / kg body weight of 1 every 3 weeks (21-day cycle) in the form of an intravenous drip infusion. Treatment with Quds ® should continue until evidence of disease progression trenbolone enanthate cycle or unacceptable toxicity. The first dose is recommended to be administered as a 90-minute intravenous drip infusion. it is necessary to watch the patient during the first infusion, and at least 90 minutes after its completion for the onset of fever , chills or other infusion reactions. Also, a careful examination of the injection site for a possible formation of subcutaneous infiltration. If prior infusion was well tolerated, the next infusion can be carried out for 30 minutes while continuing to monitor the patient for at least 30 minutes after the infusion. It is necessary to reduce the infusion rate or time to stop administering the drug Quds ® with the appearance of the patient’s symptoms of infusion reactions. In the event of a life-threatening infusion reactions therapy with Quds ® should be completely discontinued.medications for the treatment of potential infusion reactions, allergic / anaphylactic type, as well as equipment for emergency treatment should be trenbolone enanthate cycle available for immediate use. Skip to the planned introductionwhen skipping a planned introduction of the drug Quds ® is necessary before a drug can be put in the recommended dose, and the infusion rate may be the same, in which the prior infusion was well tolerated by the patient. Do not wait for the next scheduled cycle. Timetable for the introduction of the drug should be adjusted to maintain a 3-week interval between doses. Correction dose Possible measures to address the symptoms of adverse reactions are dose reduction, temporary treatment interruption or total cessation of drug therapy Quds ® . The relevant recommendations are listed below in Tables 1-5. If the dose of the drug Quds ® was reduced, the increase can not be subsequent administrations.

Buy steroids in our shop

trenbolone enanthate stack

Published / by admin

The lowest level of white blood cell trenbolone enanthate stack count and platelets observed after 7-14 days, the restoration of blood picture is usually 21 days after completion of the course. From the digestive system: nausea and vomiting. Rarely – stomatitis, abnormal liver function, usually manifests itself in the form of increased liver enzymes and / or serum bilirubin. From the urinary system: hemorrhagic cystitis, dysuria, frequent urination and other symptoms of inflammation of the bladder (blood in the urine, painful urination ), renal dysfunction (increased concentration of creatinine and urea in serum, decreased trenbolone enanthate stack creatinine clearance, glycosuria). There may also be proteinuria and metabolic acidosis. From the nervous system: disorientation, confusion, hallucinations, agitation fatigue, encephalopathy; less often – dizziness; rarely – seizures, coma, peripheral neuropathy. Reproductive system: dysfunction of the sex glands (azoospermia, amenorrhea). Skin and skin appendages: reversible alopecia, photosensitivity Local reactions: redness, swelling or pain at the injection site Other: cardiotoxic action, immunosuppression, infectious complications, slowing the rate of healing of wounds, pulmonary symptoms (cough or shortness of breath), fever, allergic reactions,faster development and pronounced the major side effects. Treatment: symptomatic, with obligatory use of mesna.

Interaction with other medicinal products
In an application with drugs that cause myelotoxic, neurotoxic and nephrotoxic effects may be increased side effects.
When used together with inducers of microsomal liver enzymes may increase the formation of alkylating metabolites. In an application enhances the hypoglycemic effect of hypoglycemic drugs. Allopurinol strengthens myelosuppression. Mesna reduces nephrotoxicity.
Ifosfamide may enhance skin reactions to radiation.
Simultaneous treatment with warfarin can reduce blood clotting and increase the risk of bleeding.

special instructions

  • Before treatment is necessary readjustment of foci of chronic infection and correction of possible electrolyte imbalance.
  • At the time of treatment should be regularly monitored picture peripheral blood (especially paying attention to the number of neutrophils and platelets), laboratory parameters of liver function, kidney and urine regularly for the presence of red blood cells, the appearance of which may precede the development of hemorrhagic cystitis.
  • If impairment of renal function and urinary flow rate may increase the toxic effect of the drug on the central nervous system, and therefore you may need to reduce the dose of ifosfamide.
  • To ensure the elimination of uric acid patients should consume enough fluids.
  • At the first signs of inflammation of the bladder or the appearance of blood in the urine, ifosfamide therapy should be discontinued.
  • In the treatment with ifosfamide is trenbolone enanthate stack possible to suppress the natural defense mechanisms, the development of antibodies in the patient’s body in response to the vaccine may be reduced.
  • Women and men during treatment and for 3 months after treatment with ifosfamide should use reliable methods of contraception.

    Effects on ability to drive and use machines
    During drug therapy may experience nausea and vomiting, as well as the phenomenon of encephalopathy, which may affect the ability to drive a car or work with other mechanisms. Therefore, you should refrain from driving and other vehicles! It should also work with power tools and machinery!

    Product form
    Powder for solution for infusion 0.2 g; 0.5 g; 1.0 g; 2.0 g to 0.2 g or 0.5 g vials of glass tubes for packaging and storage of medicines 10 ml capacity hermetically sealed with rubber stoppers mixture crimped aluminum caps.
    As 1.0 g or 2.0 g in bottles with a capacity of 25 ml injection of imported flint glass or 50 ml, respectively, sealed with rubber stoppers made ??of rubber mixture, crimped caps aluminum.
    1, 5 or 10 vials, together with instructions trenbolone enanthate stack for use in a stack of cardboard boxed or chromium-ersatz.
    50 vials with 10 instructions for use in a box made ??of cardboard for consumer packaging (for hospitals).

    Storage conditions
    List B.
    In dry, dark place at a temperature no higher than 25 ° C. In the reach of children!

    Shelf life
    2 years.
    Do not use after the expiry date stated on the package.


    where to get clenbuterol

    trenbolone enanthate gains

    Published / by admin

    Synthetic derivative of imidazole. It provides local pritivogribkovoe and antibacterial action. Inhibits ergosterol biosynthesis, regulating the permeability of cell walls of microorganisms. Easily soluble in lipids and penetrates well into tissue. It is active against dermatophytes trenbolone enanthate gains Trichophyton, Microsporum, Epidermophyton, yeast-like fungi of Candida genus, and Malassezia furfur (Pityrosporum orbiculare), causing pityriasis versicolor and Corinebacterium minutissimum, some Gram-positive bacteria (streptococci, staphylococci).
    When applied to the skin is negligible systemic absorption.
    Fungal skin, mucous membranes and scalp pityriasis versicolor, erythrasma.
    Hypersensitivity to one of the components of the preparation.
    Pregnancy and lactation
    Use of the drug during pregnancy is possible only in cases where the potential benefit to the mother outweighs the potential risk to the fetus. If necessary, use during lactation should decide the issue of termination of breastfeeding.
    Dosage and administration:

    The cream is applied to the affected skin and rub gently. The procedure is performed 1 time per day for athlete’s foot, hands and body; multi-colored lichen, 2 times a day (morning and evening). Treatment should be continued for a further 2 weeks, to prevent recurrence of athlete’s foot after the resolution of clinical signs.
    Side effect:

    Ifenek usually well tolerated, even in the case of trenbolone enanthate gains sensitive skin. In rare cases, it may cause irritation, burning sensation and itching, redness, rash. With prolonged use – hyperpigmentation and atrophic skin changes. If after treatment have any side effects not listed in this information, then they should be to inform the doctor.
    Interaction with other drugs:

    Clinical trials and use of the drug in medical practice trenbolone enanthate gains did not reveal any incompatibility or interactions with other drugs. It is recommended to inform the doctor about the simultaneous treatment of other drugs.
    Special instructions:

    For external use only. If no effect within a specified trenbolone enanthate gains time therapy should discontinue treatment and reconsider the diagnosis. When the first symptoms indicative of hypersensitivity or irritation, it is necessary to cancel the drug. Avoid getting product in eyes.
    Product form:

    Cream for external application of 1%. At 30 grams of the drug in an aluminum tube, epoxy-coated inside of the protective resin, aluminum protective layer of the trenbolone enanthate gains first opening, sealed with a cap of LDPE. On 1 tuba together with instructions for use in a carton box.
    Shelf life:
    3 years.
    Do not use beyond the expiration date printed on the package.
    Storage conditions:

    The temperature is not above 25 ° C. Keep out of the reach of children.
    Conditions of supply of pharmacies:

    Without a doctor’s prescription. steroiden kaufen

    steroide kaufen deutschland

    anabolika steroide kaufen

    trenbolone enanthate dosage

    Published / by admin

    Candidiasis of the mucous membrane trenbolone enanthate dosage of the mouth, keratomikoz; onychomycosis caused by dermatophytes or yeasts; systemic mycoses – systemic aspergillosis and candidiasis, cryptococcosis (including cryptococcal meningitis) in immunokompromitirovannyh persons and cryptococcosis of the central nervous system, regardless of the immune status at treatment failure 1st line; histoplasmosis, blastomycosis, sporotrichosis, paracoccidioidomycosis; Other rare system and tropical mycoses.

    Kidney and trenbolone enanthate dosage liver failure, peripheral neuropathy, risk factors: Chronic heart failure (ischemic heart disease, damage to the heart valves, severe pulmonary disease, including chronic obstructive pulmonary disease, a condition accompanied by edema syndrome), hearing loss, simultaneous receiving blockers of slow calcium channels, children and old age.

    Dosing and Administration
    Inside. Immediately after a meal. Capsules are swallowed whole.
    Elimination of the drug itraconazole from skin trenbolone enanthate dosage and nail tissue is slower than from plasma. Thus, the optimal clinical and mycological effects are reached 2-4 weeks after the end of treatment for skin infections and 6-9 months after the end of treatment of nail infections.
    The duration of treatment may be adjusted depending on the clinical picture of treatment:

    Side effects: the part of the trenbolone enanthate dosage gastrointestinal tract: dyspepsia (nausea, vomiting, diarrhea, constipation, loss of appetite), abdominal pain. From the hepato-biliary system: a reversible increase in “liver” enzymes, hepatitis and in very rare cases, itraconazole develop severe hepatotoxicity, including cases of acute liver failure with fatal consequences. from the nervous system: headache, dizziness, peripheral neuropathy. immune system: anaphylactic, anafilaktoidiye and allergic reactions. For the skin: a very rare cases – exudative erythema multiforme (Stevens-Johnson syndrome), skin rash, pruritus, urticaria, angioedema, alopecia, photosensitivity. Other: menstrual disorders, hypokalemia, edema syndrome, chronic heart failure and pulmonary edema.

    No data. In case of accidental overdose, supportive measures should be used. As to gastric lavage and, if necessary, to assign the activated carbon within the first hour. Itraconazole not appear in hemodialysis. Any specific antidote does not exist.

    Interactions with other drugs

    • Drugs affecting the absorption of itraconazole Drugs that reduce gastric acidity, reduce the absorption of itraconazole, which is related to the solubility of the capsule shell.
    • Drugs affecting the metabolism of itraconazole. Itraconazole is mainly metabolized by isoenzyme CYP3A4. the interaction of itraconazole has been investigated with rifampicin, rifabutin and phenytoin, which are potent inducers of CYP3A4 isoenzyme. The study found that, in these cases, the bioavailability of itraconazole and gidroksiitrakonazola significantly reduced, which leads to a substantial reduction efficacy. Concomitant use of itraconazole with these drugs, which are potential inducers of microsomal liver enzymes is not recommended. Studies of interaction with other inducers of hepatic microsomal enzymes such as carbamazepine, phenobarbital and isoniazid were not conducted, however, similar results can be expected. Potent inhibitors isoenzyme CYP3A4, such as ritonavir, indinavir, clarithromycin and erythromycin, can increase the bioavailability of itraconazole.
    • Effect of itraconazole on the metabolism of other drugs. Itraconazole can inhibit the metabolism of drugs, cleavable isoenzyme CYP3A4. The result may be increased or prolonging their action, including side effects. Before taking concomitant medications, you should consult with your doctor about the metabolic pathways of the drug specified in the instruction on medical trenbolone enanthate dosage application. After the cessation of treatment in the plasma concentration of itraconazole is gradually reduced depending on the dose and duration of treatment (see. Section Pharmacokinetics ). This should be taken into account in the discussion of the floating effect of itraconazole on concomitant medications.

    Examples of these medications include:
    Drugs that should not be administered concurrently with itraconazole:

    • Terfenadine, astemizole, mizolastine, cisapride, dofetilide, quinidine, pimozide, levacetylmethadol, sertindole – the combined use of these drugs with itraconazole can cause increase in the concentration of these substances in plasma and increase the risk of QT prolongation, and in rare cases -vozniknovenie atrial ventricular arrhythmia (torsade de pointes).
    • metabolized by CYP3A4 isoenzyme inhibitors CoA reductase GMG such as simvastatin and lovastatin,
    • midazolam and oral triazolam,
    • ergot alkaloids such as dihydroergotamine, ergometrine, ergotamine and metilergometrin,
    • Blockers “slow” calcium channels – in addition to possible pharmacokinetic interactions associated with common pathway of metabolism with the participation of CYP3A4 isoenzyme, blockers “slow” calcium channel blockers can have negative inotropic effect, which is enhanced by concomitantly with itraconazole.

    Formulations in which assignment must monitor their concentrations in plasma, by the action, side effects. In the case of co-administration with itraconazole dose of these preparations, if necessary, should be reduced.

    • Indirect anticoagulants;
    • HIV protease inhibitors such as ritonavir, indinavir, saquinavir;
    • Some anti-cancer drugs such as vinca alkaloids, busulfan, docetaxel, trimetrexate;
    • metabolized by CYP3A4 isoenzyme blockers “slow” calcium channel blockers, such as verapamil and derivatives of dihydropyridine;
    • Some immunosuppressive agents: cyclosporine, tacrolimus, sirolimus (also known as rapamycin);
    • Some metabolized isoenzyme CYP3A4 inhibitors CoA reductase GMG such as atorvastatin;
    • Some glucocorticosteroids such as budesonide, dexamethasone, and methylprednisolone;
    • Other drugs: digoxin, carbamazepine, buspirone alfentanil, alprazolam, brotizolam, midazolam intravenous, rifabutin, ebastine, reboxetine, cilostazol, dizoliramid, eletriptan, halofantrine, repaglinide.

    The interactions between itraconazole and zidovudine and fluvastatin were found.
    There was no effect of itraconazole on the metabolism of ethinyl estradiol and norethisterone.

    1. The effect on the plasma protein bond.

    in vitro studies demonstrated no interaction between itraconazole and other drugs such as imipramine, propranolol, diazepam, cimetidine, indometacin, tolbutamide and sulfamethazine upon binding to plasma proteins.


    special instructions

    • Women of childbearing potential taking Itraconazole, you must use reliable methods of contraception throughout the course of treatment until the onset of the first menstrual period after its completion.
    • It found that itraconazole has a negative inotropic effect. At the same time taking itraconazole and calcium channel blockers, which may have the same effect, you must be careful. It reported cases of congestive heart failure associated with the reception of itraconazole. Itraconazole should not be taken in patients with chronic heart failure, or with the presence of this disease in history except in cases where the potential benefit significantly outweighs the potential risk. When an individual assessment of the ratio of benefits and risks should be taken into account such factors as the seriousness of the indications, dosage regimen and individual risk factors for congestive heart failure. Risk factors include the presence of heart disease, such as coronary heart disease or valvular disease; serious lung diseases, such as obstructive lung disease; kidney failure and other diseases, accompanied by edema. Such patients should be informed about the signs and symptoms of congestive heart failure.Treatment should be given with caution, and the patient should be monitored for the onset of symptoms of congestive heart failure. When they appear receiving itraconazole should be discontinued.
    • At low acidity of the stomach: in this condition the absorption of itraconazole capsules violated. Patients taking antacids (e.g., aluminum hydroxide), it is recommended to use them not earlier than 2 hours after administration of itraconazole capsules. Patients with achlorhydria or applying blockers H 2 histamine receptors, and proton pump inhibitors, are advised to take itraconazole capsules with drinks containing cola.
    • In very rare cases, itraconazole develop severe hepatotoxicity, including cases of acute liver failure with fatal consequences. In most cases it is observed in patients who already had liver disease, patients with other serious illnesses treated by systemic itraconazole therapy indications, as well as patients who received other drugs having hepatotoxic. Some patients have no obvious risk factors identified in relation to liver damage. Several of these cases occurred in the first month of therapy, and some – in the first week of treatment. In this connection, it is recommended to regularly monitor liver function in patients receiving treatment with itraconazole. Patients should be warned of the need to immediately contact your doctor in case of symptoms, suggesting the occurrence of hepatitis, such as: anorexia, nausea, vomiting, weakness, abdominal pain, and dark urine. In the case of the appearance of these symptoms should immediately discontinue therapy and to conduct a study of liver function.Patients with a higher concentration of “liver” enzymes or liver disease in the active phase, or at any adjourned toxic liver damage when taking other medications should not be given itraconazole treatment unless the expected benefit justifies the risk of liver damage. In these cases, during the treatment to monitor the concentration of “liver” enzymes.
    • Abnormal liver function: itraconazole is metabolized primarily in the liver. Since patients with impaired hepatic function a full half-life of itraconazole increased slightly, it is recommended to carry out monitoring of itraconazole concentration in plasma and adjust the dose if necessary.
    • Renal function: As patients with complete renal failure the half-life of itraconazole increased slightly, it is recommended to monitor the concentration of itraconazole in plasma and adjust the dose if necessary.
    • Patients with immunodeficiency: the bioavailability of itraconazole when given orally can be reduced in some patients with impaired immunity, for example, in neutropenic patients, patients with AIDS or undergoing organ transplants.
    • Patients with systemic fungal infections that threaten life as a result of the pharmacokinetic characteristics of Itraconazole capsules are not recommended to start treatment of systemic fungal infections that threaten patients’ lives.
    • AIDS patients.
    • The attending physician should evaluate the need for the appointment of maintenance therapy to AIDS patients who have received prior treatment for systemic fungal infections such as sporotrichosis, blastomycosis, histoplasmosis or cryptococcosis (meningeal how and nemeningealnogo), in which there is a risk of recurrence.
    • Clinical data on the use of Itraconazole capsules in pediatric patients is limited. Itraconazole capsules should not be administered to children, except in cases where the expected benefits outweigh the potential risk.
    • The treatment should be discontinued when a peripheral neuropathy that might be associated with the reception of itraconazole capsules.
    • There is no evidence of cross-hypersensitivity to itraconazole and other azole antifungal agents.


    Effects on ability to drive and operate machinery
    Itraconazole can cause dizziness and other side effects, which may affect the ability to drive vehicles and other machinery requiring attention during operation.

    Form release
    capsules 100 mg.
    In 1,3,4,5,6 or 7 capsules in blisters.
    In 1,2,3,4 or 5 contour cell package together with instructions for use in a pile of cardboard.

    In a dry, dark place at a temperature no higher than 25 ° C. Keep out of the reach of children.

    Shelf life
    3 years. Do not use beyond the expiration date printed on the package.

    buy hgh on line trenabol information buy hgh injections for bodybuilding